Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$12.08
+0.6%
$9.39
$6.42
$12.53
$1.58B1.232.80 million shs1.00 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.64
-0.4%
$14.41
$12.79
$55.70
$1.56B0.982.16 million shs1.10 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$8.50
-1.8%
$7.58
$4.58
$9.48
$433.58M1.881.12 million shs517,287 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$17.79
-1.0%
$15.98
$8.46
$25.29
$1.60B0.741.54 million shs1.05 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-0.17%0.00%+39.33%+45.22%+86.78%
Biohaven Ltd. stock logo
BHVN
Biohaven
-3.27%+1.77%+6.23%-5.14%-64.23%
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.69%-4.63%+29.06%+39.23%-5.56%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+1.93%-0.44%+13.59%+14.46%+101.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.9781 of 5 stars
1.53.00.00.03.42.53.1
Biohaven Ltd. stock logo
BHVN
Biohaven
3.7896 of 5 stars
4.53.00.00.02.82.50.6
CryoPort, Inc. stock logo
CYRX
CryoPort
3.6298 of 5 stars
4.51.00.00.01.62.51.9
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.5868 of 5 stars
3.43.00.00.02.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$12.00-0.66% Downside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$54.23270.53% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
3.00
Buy$12.0041.18% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.2181.08% Upside

Current Analyst Ratings Breakdown

Latest CYRX, TVTX, BHVN, and AUPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$59.00 ➝ $60.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $30.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $50.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$63.00 ➝ $54.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$57.00 ➝ $52.00
8/12/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $49.00
8/10/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $31.00
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.00
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M6.76$0.31 per share39.01$2.55 per share4.74
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$1.27 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.86N/AN/A$9.53 per share0.89
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M6.80N/AN/A$0.37 per share48.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.4328.0921.57N/A23.31%20.06%13.81%11/6/2025 (Estimated)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%N/A
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M$1.336.39N/AN/A37.21%-9.79%-5.42%11/6/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)

Latest CYRX, TVTX, BHVN, and AUPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.94-$1.94N/A-$1.94$0.41 millionN/A
8/6/2025Q2 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.29-$0.09$2.05$41.74 million$45.45 million
7/31/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.17$0.16-$0.01$0.16$64.27 million$70.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.18
5.23
4.63
Biohaven Ltd. stock logo
BHVN
Biohaven
1.91
3.82
3.82
CryoPort, Inc. stock logo
CYRX
CryoPort
0.39
16.24
15.47
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.50
2.00
1.98

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
Biohaven Ltd. stock logo
BHVN
Biohaven
16.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300131.63 million115.57 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239105.79 million88.86 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.07 million45.06 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46089.14 million85.40 millionOptionable

Recent News About These Companies

Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to "Buy"
TVTX FY2025 EPS Forecast Boosted by Cantor Fitzgerald
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.08 +0.07 (+0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$12.04 -0.04 (-0.29%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Biohaven stock logo

Biohaven NYSE:BHVN

$14.64 -0.06 (-0.44%)
Closing price 03:59 PM Eastern
Extended Trading
$14.48 -0.16 (-1.07%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$8.50 -0.16 (-1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$8.49 -0.01 (-0.06%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$17.79 -0.18 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$17.79 0.00 (0.00%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.